NCT04984668View on ClinicalTrials.gov

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor
Interventions
DRUG

GT90001+KN046

GT90001 7.0mg/Kg， KN046 5mg/Kg

DRUG

GT90001+KN046

GT90001 7.0mg/Kg ， KN046 3mg/Kg

DRUG

GT90001/KN046

GT90001 4.5mg/Kg / KN046 5mg/Kg

DRUG

GT90001+KN046

GT90001 4.5mg/Kg， KN046 3mg/Kg

DRUG

GT90001+KN046

GT90001 3mg/Kg ， KN046 3mg/Kg

Trial Locations (1)

Unknown

RECRUITING

Chi-Mei Medical Center, Tainan City

All Listed Sponsors
collaborator

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY

lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT04984668 - A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | Biotech Hunter | Biotech Hunter